T-CELL LYMPHOMA

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This study tests the drug ruxolitinib in people with T or NK cell lymphoma that has come back or not responded to prior treatment. Ruxolitinib works by blocking a protein called JAK, which helps these cancer cells survive. The goal is to see if the drug can shrink tumors or contr…

This study tests a new type of CAR-T cell therapy designed to target a protein called CD5 on cancer cells. It is for people with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to other treatments. The therapy uses special nanobodies to …

This early-phase study tests a new treatment called CD4CAR for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The…

This early-stage trial tests a new drug called BI-1808, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma that have not responded to standard treatments. The main goals are to check s…

This study tests adding the drug mogamulizumab to standard chemotherapy for people with aggressive T-cell lymphoma, a type of blood cancer. About 22 adults with newly diagnosed or returning lymphoma will receive the combination treatment. The goal is to see if more patients achie…

This study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…

This early-phase trial tests a new form of the drug fenretinide (ST-001) in people with T-cell non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard therapy. The main goals are to find the safest dose and to watch for side effects. About 46 adults with …

This study tests enasidenib, a drug that targets cancer cells with a specific IDH2 mutation, in people with angioimmunoblastic T-cell lymphoma (AITL). The drug is given alone or with rituximab. The goal is to see if it safely shrinks tumors. About 25 adults whose lymphoma has ret…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study is creating a large database of information from 1,000 people with T-cell lymphoma. Researchers will collect medical details and tumor samples to learn more about the disease. The goal is to improve future care and outcomes for patients. No new treatments are being tes…